Subscribe to RSS
DOI: 10.1055/s-0035-1545299
Effect of Sarcosine (a Glycine Transport 1 Inhibitor) and Risperidone (an Atypical antipsychotic Drug) on MK-801 Induced Learning and Memory Deficits in Rats
Publication History
received 28 October 2014
accepted 27 January 2015
Publication Date:
24 February 2015 (online)
Abstract
The present study was carried out to evaluate whether the combined administration of sarcosine with risperidone possess any advantageous effects on dopaminergic and NMDA receptor-mediated glutamatergic neurotransmissions as compared to single drug administration in rats. The Wistar rats were divided into 7 groups each with different treatments. MK-801 (0.1 mg/kg, i.p.) was injected as single dose on 14th day for inducing learning and memory deficits in animals. Sarcosine (300 and 600 mg/kg, i.p.) and risperidone (0.2 mg/kg, i.p.) were administered daily for 14 days. Spatial habituation learning and hole board tests were performed on 14th day followed by measurement of GABA and 5-HT levels in brain tissues of rats. Pretreatment of sarcosine (600 mg/kg, i.p.) non-significantly improved learning and memory deficits induced by non-competitive NMDA receptor antagonist MK-801, significantly increased the GABA and decreased the 5-HT levels (p<0.05). Combined administration of sarcosine (300 mg/kg, i.p.) with risperidone (0.1 mg/kg, i.p.) synergistically improved cognitive deficits significantly, decreased % errors in hole board learning test, and increased centre time, corner time in spatial habituation learning test (p<0.05). The combined administration also potentiated the GABA and decreased 5-HT levels, indicating that the increased synaptic glycine concentrations may enhance NMDA receptor function which is directly linked with increased GABAergic transmission in striatum region and decreased 5-HT levels showed antagonistic action hence, enhancing the cognition. Our results suggest that combined administration of sarcosine with risperidone may strengthen glutamatergic tone in striatum. Thus, it may be a novel regime to improve psychotic symptoms and cognitive deficit in schizophrenia.
-
References
- 1 Lindenmayer JP. Treatment refractory schizophrenia. Psychiat Q winter 2000; 71: 373-384
- 2 Leucht S, Barnes TRE, Kissling M et al. Relapse Prevention in Schizophrenia with New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized. Controlled Trials 2003; 160: 1209-1222
- 3 Arnt J, Skarsfeldt T, Hyttel J. Differentiation effects of classical and novel antipsychotic using animal model. Int Clin Psychopharmocol 1997; 12 (Suppl. 01) S9-S17
- 4 Yoon JK, Kim DE, Koo JS. Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer. J Transl Med 2014; 12: 149 Published online May 28, 2014 DOI: 10.1186/1479-5876-12-149.
- 5 Bartolomeis AD, Sarappa C, Magara S et al. Targeting glutamate system for newer antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol 2012; 682: 1-11
- 6 Chen HH, Stoker A, Markou A. The glutamatergic compound sarcoine and N-acetylcysteine ameliorate prepluse inhibition defict in metabotrophic glutamate 5 receptor knockout mice. Psychopharmacology 2010; 209: 343-350
- 7 De Lama MN, Laranja DC, Bromberg E et al. Pre- or post training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behavioural Brain Res 2005; 156: 139-143
- 8 Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub chronic PCP induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Res 2007; 184: 31-38
- 9 Meltzer HY, Mcgurk SR. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull 1995; 25: 233-255
- 10 Hashimoto K. Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J 2010; 4: 10-19
- 11 Hashimoto K, Fujita Y, Ishima T et al. Phencyclidine-induced cognitive deficits in mice is improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Euro Neuropsychopharmacol 2008; 18: 414-421
- 12 Strzelecki D, Szyburska J, Jabłońska JR. Two grams of sarcosine in schizophrenia Is it too much? A potential role of glutamate-serotonin interaction. Neuropsychiatric Disease and Treatment 2014; 10: 263-266
- 13 Dai H, Krost M, Carey RJ. A new methodological approach to the study of habituation: The use of positive and negative behavioural indices of habituation. J Neurosci Methods 1995; 62: 169-174
- 14 Brown GR, Nemes C. The exploratory behaviour of rat in the hole- board apparatus: Is head-dipping a valid measure of neophilia?. Behaviour Process 2008; 78: 442-448
- 15 Babu CS, Kesavanarayanan KS, Kalaivani P et al. A Simple Densitometric Method for the Quantification of Inhibitory Neurotransmitter Gamma-Amino butyric Acid (GABA) in Rat Brain Tissue. Chromatography Research International Volume 2011; 2011 Article ID 732409, 5 pages http://dx.doi.org/10.4061/2011/732409
- 16 Curzon G, Green AR. Rapid method for the determination of 5- hydroxyl trytamine and 5-hydroxyindolacetic acid in small region of rat brain. Life science Oxford 1968; 7: 653-657
- 17 Harvey RJ, Benjamin KY. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nature Reviews Drug Discovery 2012; 12: 866-885
- 18 Wojciech Z, Gunter Q, Wojciech D. Infusion of (+)-MK-801 and Memantine contrasting effects on maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296: 239-246
- 19 Nakajima M, Inui A, Miura M et al. Effects of pancreatic polypeptide family peptides on feeding and learning behaviour in mice. J Pharmacol Exp Ther 1994; 268: 1010-1014
- 20 Sutcliffe JS, Marshall KM, Neill JC. Influence of gender on working memory in the novel object recognition task in the rat. Behav Brain Res 2007; 177: 117-125
- 21 Black MD, Varty GB, Arad M et al. Procognitive and antipsychotic efficacy of Glycine transporter inhibiters (Gly-T I) in acute neurodevelopmental model of schizophrenia: Latent inhibition study in rat. Psychopharmacol (Berl) 2009; 202: 385-396
- 22 Singer P, Feldon J, Yee BK. Interactions between the glycine transporter 1 (GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour. Eur Neuropsychopharmacol 2009; 19: 571-580
- 23 Coan EJ, Collingridge GL. Effects of phencyclidine, SKF10, 047 and related psychotomimetic agents on N-methyl-D-aspartate receptor mediated synaptic responses in rat hippocampal slices. Br J Pharmacol 1987; 91: 547-565
- 24 Alberati D, Moreau J, Lengyel J et al. Glycine reuptake inhibitor rg1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012; 62: 1152-1161
- 25 Javitt DC, Sershen S, Hashim A et al. Reversal of phencyclidine-induced hyperactivity by glycine and the Glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997; 17: 202-204
- 26 Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1995; 148: 1301-1308
- 27 Kleppner SR, Tobin AJ. GABA signalling: therapeutic targets for epilepsy, Parkinson disease and Huntington disease. in opinion on therapeutic targets 2001; 5: 219-239
- 28 Ginovart N, Kapur S. Role of Dopamine D2 Receptors for Antipsychotic Activity. In Gross G, Geyer MA. (eds.) Current Antipsychotics, Handbook of Experimental Pharmacology. 2012. DOI: 10.1007/978-3-642-25761-2_2 # Springer-Verlag; Berlin Heidelberg:
- 29 Gernot R, Bettina P, Jacques M. Glutamate receptor function in learning and memory. Behav Brain Res 2003; 140: 1-47
- 30 Lydiard RB. The role of GABA in anxiety disorder. J Clinical Psychiatry 2003; 64: 21-27